Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Long-Awaited Nationwide Opioid Settlement To Move Forward For Teva

Participation Has Been Confirmed For 48 Of The 50 US States

Executive Summary

Teva has all but two US states on board for its long-hoped-for nationwide settlement to resolve opioid-related claims against the firm.

You may also be interested in...



Teva Quits PhRMA As Financial, Policy Challenges Loom For The Brand/Generic Hybrid Giant

With a leadership position in the US generics association and a new CEO focused on how to reallocate resources, Teva leaves the brand trade association after a review of the ‘effectiveness and value of engagements.’

Five Big Legal Stories From 2022

Generics Bulletin looks back at a selection of the most significant legal stories from 2022, including a major victory in the UK on the Eliquis blood thinner giant and continued action on generic label carve outs, which has the potential to reverberate through the US industry.

2022 Hires Reflect Global Challenges And Opportunities

Executive changes in 2022 reveal how the industry is adjusting to a volatile post-COVID environment.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel